ホーム › 胃癌 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける胃癌の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、胃癌に関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
被験者募集中第2/3相
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
被験者募集中第2相
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
被験者募集中第3相
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
被験者募集中第1相
- AHN West Penn Hospital, Pittsburgh
他の都市における胃癌の試験
- Houston, TX42件の研究
- Boston, MA32件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- Dallas, TX19件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Grand Rapids, MI18件の研究
- Washington, DC16件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 頭頸部扁平上皮癌22件の研究
- 脳卒中22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。